Launched on the French market in 1989, Dotarem® is currently available in over 70 countries.
First launched in 2002 in France, Artirem® is commercialized in nine countries.
Optimark® was launched in 2000 in the USA.
Sales of Optimark® have ended in European Union countries (July 26, 2017). In order to ensure a smooth transition and continuous supply for patients, Optimark® phase out is progressively implemented in other geographic areas until end of 2019.
English / Français